|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
October 2005FeaturesCover Story Specialty Pharmacy at a CrossroadConsolidation of the specialty pharmacy business indicates a repositioning to buy new market channels, reduce costs, and compete in a burgeoning market. The challenge for SP is to prove its value to payers. Some companies are doing that on the basis of price or by offering care management services. Here’s a look at a business in transition as it redefines itself for the biologics era. Business The Rise and Role of Specialty PharmacyOver the last 30 years, specialty pharmacy has grown from a notion to a cottage industry to being on the cusp of becoming a major force in healthcare delivery. Regulation A Look at Part D Implementation in ActionAs the Medicare prescription drug benefit moves toward its January implementation, thousands of people in the insurance and pharmaceutical industries are doing their best to work the nuances of the plan to their competitive advantage. Benefit Design Are Biotech and Consumer-Directed Healthcare Compatible?The emergence of the consumer as decision maker could spur careful analyses of the value of biotech therapies and diagnostics relative to alternatives. Venture Capital A Business Model for a New Generation of Diagnostics CompaniesVenture capital has tended to shy away from diagnostics companies, whose products are not predicated on the blockbuster model of pharmaceuticals. But several new
diagnostics companies are developing products that hold immense potential to improve healthcare delivery. Here’s why venture investors should take another look at the diagnostics area. Leading Edge One Drug, Many UsesThis year’s ASCO meeting was, in essence, a showcase for multitargeted therapeutics – those with similar makeup but many potential uses. In what is rapidly becoming a hallmark of biotech drug development, the idea that a basic mechanism of action can be applied to disparate diseases has the potential to move biotechnology forward to better therapies
and a more efficient R&D process. DepartmentsOpeners ‘Specialty’ the Key Part of SPPutting the “specialty” in pharmacy. Editorial Base HitsDavid B. Nash, MD, MBA, roots for a base hit. Washington Watch Push Is on To Keep Results of Genetic Testing a SecretHeavy hitters get behind bill to keep results of genetic tests a secret. DrugTrack Approvals, FDA actions, Clinical Trials.
Bob Carlson Diagnostics and Devices HCV Testing Cost-Effective Alternative to Treating Advanced DiseaseHCV testing: cost-effective, considering the alternative. Biotech Business Venture Uses Industry’s Might for a Noble FightBiotech’s potential tapped to combat the third world’s biggest killers. In the Pipeline Balancing Drug and Payer Costs
Katherine T. Adams |
|||||